v3.25.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2024
SCHEDULE OF REDEEMABLE ORDINARY SHARE SUBJECT TO POSSIBLE REDEMPTION

At December 31, 2024 and 2023, the redeemable ordinary shares subject to possible redemption reflected in the consolidated balance sheet is reconciled in the following table:

 

Redeemable ordinary shares subject to possible redemption at December 31, 2023  $19,901,169 
Plus:     
Remeasurement of carrying value to redemption value   548,676 
Less:     
Redemption   (13,781,323)
Redeemable ordinary shares subject to possible redemption at December 31, 2024  $6,668,522 
SCHEDULE OF RECONCILIATION OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE

 

    Class A     Class B     Class A     Class B  
    For year ended     For year ended  
    December 31, 2024     December 31, 2023  
    Class A     Class B     Class A     Class B  
Basic and diluted net (loss) income per share:                                     
Numerator:                                
Allocation of net (loss) income   $ (12,537,472   $ -     $ 3,831,570     $ 632,509  
Denominator:                                
Weighted average shares outstanding     8,244,188       -       16,461,668       2,717,466  
Basic and diluted net (loss) income per share   $ (1.52   $ -     $ 0.23     $ 0.23  
Aspire Biopharma Inc [Member]  
SCHEDULE OF RESTATEMENT CONSOLIDATED FINANCIAL STATEMENTS

The effect of the restatement of the Balance Sheets for December 31, 2023, is as follows:

 

SCHEDULE OF RESTATEMENT CONSOLIDATED FINANCIAL STATEMENTS

   As Previously Reported   Restated   Effect of the  
   December 31, 2023   December 31, 2023   Restatement 
ASSETS:               
Current Assets:               
Cash  $11,174   $11,174   $- 
Prepaid Expenses   35,000    35,000    - 
Total Current Assets   46,174    46,174    - 
Total Assets  $46,174   $46,174   $- 
                
LIABILITIES AND STOCKHOLDERS’ EQUITY:               
Current Liabilities:               
Accounts Payable  $172,773   $172,773   $- 
Short-term loans from shareholders   360,636    360,636    - 
Other Current Liabilities   626    626    - 
Total Current Liabilities   534,035    534,035    - 
                
Total Long-Term Liabilities   -    -    - 
Total Liabilities  $534,035   $534,035   $- 
                
Stockholders Equity:               
Common stock - Par Value $0.001   221,500    22,000    (199,500)
Additional paid-in-capital   758,000    957,500    199,500 
Accumulated Deficit   (1,467,361)   (1,467,361)   - 
Total Equity   (487,861)   (487,861)   - 
TOTAL LIABILITIES AND EQUITY  $46,174   $46,174   $-